What are HLA-matched cell platforms?

Cell lines are created from patient-derived blood and tumor tissue. Our cell platforms are developed from the same patient and were HLA-typed to ensure they are from the same patient.

What are the advantages of HLA-matched T cell and Tumor Cell Lines?

null

HIGHER SPECIFICITY

Higher specificity results in exquisite sensitivity between the TILs and tumors, resulting in an increased ability to detect the impact factors within the tumor microenvironment that could be masked by allogeneic responses
null

WELL CHARACTERIZED

Highly characterized tumors (e.g. Braf mutations and STR profiles are known). Huge panel from which one can assess the impact of potential drugs
null

ESTABLISHED DATA WITH APPROVED IMMUNE MODULATORS

Established data with anti-PD1 and anti-PD-L1 drug candidates – good for comparative studies
null

REPEAT STUDIES ACROSS ASSAY FORMATS

A standardized and reproducible system which with one can assess immune responses across various platforms
null

BROAD SPECTRUM APPLICATIONS IN CANCER

Apply readouts into other tumor types and indications
null

HIGHER SPECIFICITY

Higher specificity results in exquisite sensitivity between the TILs and tumors, resulting in an increased ability to detect the impact factors within the tumor microenvironment that could be masked by allogeneic responses.

null

WELL CHARACTERIZED

Highly characterized tumors (e.g. Braf mutations and STR profiles are known). Huge panel from which one can assess the impact of potential drugs.
null

ESTABLISHED DATA WITH APPROVED IMMUNE MODULATORS

Established data with anti-PD1 and anti-PD-L1 drug candidates – good for comparative studies.
null

REPEAT STUDIES ACROSS ASSAY FORMATS

A standardized and reproducible system which with one can assess immune responses across various platforms.

null

BROAD SPECTRUM APPLICATIONS IN CANCER

Apply readouts into other tumor types or indications

How do we offer these platforms?

null

SCHEDULED (QUICK SCREEN) ASSAYS

Each month, our team selects a cell platform and will design an assay or system with fixed readouts. The intent is to provide our partners a cost-effective and efficient way to obtain preliminary or complimentary data. Register to receive our schedule updates.

null

BUILD-A-SYSTEM

Experience partners can design an assay or system using our cell platforms suitable to their needs. Just send us an inquiry with your protocol and our team will execute.
null

BUNDLED

We offer a discounted bundle for using our cell platforms across multiple formats. Contact us to learn more.

What can we study using these cell lines?

There are several studies that can help our partners evaluate phenotypic and functional analysis across various assay formats. The well-characterized nature of our cell platforms enables us to understand the “inputs” and “outputs” in the screening of drug candidates.
  • Tumor killing assays
  • Tumor cell assays
  • Natural killer cell assays
  • Macrophage and Dendritic cell assays
  • Neutrophil assays
  • Fibroblast assays
  • Cytokine release assays
  • T cell mediated Exhaustion assay
  • T cell mediated Chemotaxis assays
  • T cell mediated cytoxicity assay
  • ADA screening
  • Titration and Isotyping
  • Neutralizing Ab
  • Binding
  • Blocking
  • Affinity
  • T cell Dependent Antibody Response (TDAR)
  • Tetanus Toxoid Recall Assay – proliferation
  • Flu antigen Recall – Antigen Response
  • CMV/EBV/Flu – Increase TNF
  • Mixed Lymphocyte Reaction (MLR) Assays
  • Mart-1 (melanoma antigen)
  • Immunophenotyping in blood or organs
  • Compliment Assays
  • Antibody Dependent Cell Cytotoxicity (ADCC)
  • Cell Dependent Cytoxicity (CDC)
  • Receptor Occupancy
  • Neutrophil/Macrophage
    • Oxidative Burst
    • Phagocytosis
    • Migration
  • Th1/Th17 Differentiation assays
  • Tumor Associated Macrophages (TAM)
  • Regulatory T cells (Tregs) Suppression assay
  • M1/M2 Macrophage assays

This is a PD-L1 sensitive tumor line

TIM-3, PD-1, CD25, CD80, HVEM, GITR, CD73, PD-L2, OX-40L, CD155, CD112, CD44, CD49a (α1 integrin), CD49b (α2 integrin), CD29 (β1 integrin), CD95 (FAS) CD54 (ICAM-1), CD11a (LFA-1a)

CTL and Tumor 001 was derived from a colon cancer patient. This HLA-matched pairing is PD-L1 sensitive.

Tumor 001

PD-L1, HVEM, OX-40L, CD155, CD112, CD44,
CD49b(α2 integrin), CD29(β1 integrin), CD95 (FAS)

Chemokines and Chemokine Receptors

CCR2,CCR3, CCL15,CCL2,CCL3,CCL4,CXCL11, CCL19,CCL21, CCL25, and CXCL9

Example studies:

  • Cytotoxity (CTL) studies
  • Immunosuppression assays to evaluate the role of Tregs and Tumro Associated Macrophages (TAMs) on CTL proliferation and apoptosis of matched tumor
  • Blocking and binding studies of known cell surface targets

 

This is a PD-1 sensitive tumor line

CTL and Tumor 002 derived from a female colon cancer patient at time of surgery. This HLA-matched cell pairing is PD-1 sensitive.

PD-1, TIGIT, OX-40, 4-1BB, CD80, CD44, CD95 CD29(β1 integrin), CD3, TCR α/β, CD95 (FAS), CD54 (ICAM-1), CD11a (LFA-1a)

Tumor 002

PD-L1, HVEM, OX-40L, CD155, CD112, CD44 CD49a (α1 integrin), CD49b (α2 integrin), CD29 (β1 integrin), CD95 (FAS)

Chemokines and Chemokine Receptors

CCR2,CCR3, CCL15,CCL2,CCL3,CCL4,CXCL11, CCL19,CCL21, CCL25, and CXCL9

Example studies:

  • Cytotoxity (CTL) studies
  • Immunosuppression assays to evaluate the role of Tregs and Tumro Associated Macrophages (TAMs) on CTL proliferation and apoptosis of matched tumor
  • Chemokine blocking studies of SDF1α and CXCR4
  • Blocking and binding studies of known cell surface targets

 

This is a PD-1 sensitive tumor line

CTL and Tumor 003 derived from a melanoma male Caucasian patient. This HLA-matched cell pairing is PD-1 and PD-L1 sensitive.

TIM-3, PD-1, 4-1BB, ICOS, CD8, CD25, CD44
CD95 (FAS),CD80(B7-1), CD29(β1 integrin), CD49b (α2 integrin), CD54 (ICAM-1), CD11a (LFA-1A)

Tumor 003

PD-L1, CD44, ICOSL, 4-1BBL, PD-L2, CD112, HVEM, CD49a (α1 integrin), CD49b (α2 integrin), CD29 (β1 integrin), CD95 (FAS)

Chemokines and Chemokine Receptors

CCR7,CCR9, CXCR3,CXCR1, CCL21,CCL25, CXCL12,CXCL19 and CXCL9

Example studies:

  • Cytotoxity (CTL) studies
  • Immunosuppression assays to evaluate the role of Tumro Associated Macrophages (TAMs) on CTL proliferation and apoptosis of matched tumor
  • Chemokine blocking studies of SDF1α and CXCR4 and affects on CTL migration
  • Blocking and binding studies of known cell surface targets

 

[mc4wp_form id=”200″]